Sepio Capital LP Purchases 7,455 Shares of Novo Nordisk A/S $NVO

Key Points

• Sepio Capital LP increased its holdings in Novo Nordisk A/S by 37.5%, acquiring an additional 7,455 shares during the first quarter, bringing its total to 27,359 shares valued at approximately $1.9 million.
• Several institutional investors, including Parkwood LLC and NFJ Investment Group LLC, made significant increases in their stakes, indicating strong interest in Novo Nordisk A/S.
• The company's stock has received mixed ratings from analysts, with a consensus rating of "Hold" and an average price target of $81.00, amidst fluctuations in its quarterly earnings and stock performance.

Sepio Capital LP grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 37.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,359 shares of the company's stock after acquiring an additional 7,455 shares during the quarter. Sepio Capital LP's holdings in Novo Nordisk A/S were worth $1,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Parkwood LLC increased its stake in Novo Nordisk A/S by 76.8% in the 1st quarter. Parkwood LLC now owns 462,571 shares of the company's stock worth $32,121,000 after acquiring an additional 200,976 shares during the last quarter. NFJ Investment Group LLC increased its stake in Novo Nordisk A/S by 826.9% in the 1st quarter. NFJ Investment Group LLC now owns 94,015 shares of the company's stock worth $6,528,000 after acquiring an additional 83,872 shares during the last quarter. NewEdge Advisors LLC increased its stake in Novo Nordisk A/S by 29.1% in the 1st quarter. NewEdge Advisors LLC now owns 432,345 shares of the company's stock worth $30,022,000 after acquiring an additional 97,377 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Novo Nordisk A/S by 1.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 96,487 shares of the company's stock worth $6,700,000 after acquiring an additional 1,407 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its stake in Novo Nordisk A/S by 6.5% in the 1st quarter. Integrated Wealth Concepts LLC now owns 26,712 shares of the company's stock worth $1,855,000 after acquiring an additional 1,630 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on NVO shares. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price for the company in a report on Wednesday, August 13th. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. HSBC cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a report on Thursday, July 31st. Finally, TD Cowen dropped their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, August 19th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Price Performance

NVO opened at $55.15 on Friday. The business has a fifty day moving average of $59.46 and a 200 day moving average of $67.51. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $138.22. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $246.23 billion, a P/E ratio of 15.15, a PEG ratio of 1.92 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.